Evidence map›Paper›PMID 40933275›Full record

ArticleMolecular therapy. Oncology2025

Effective gene immunotherapy for melanoma utilizing an advanced

Loree C Heller, Julie S Singh, Jody C Synowiec, Pavan Kumar Cherukuri, Nhat Phan, Guilan Shi, Mark J Jaroszeski, Alex Otten, Richard Heller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Loree C HellerDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Julie S SinghDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Jody C SynowiecDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Pavan Kumar CherukuriDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Nhat PhanDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Guilan ShiDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Mark J JaroszeskiDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Alex OttenDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.
Richard HellerDepartment of Medical Engineering, University of South Florida, Tampa, FL 33612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-12 (IL-12) is a potent immune stimulator that induces the proliferation and activation of natural killer (NK) and T cells and the secretion of interferon (IFN)-γ. While IL-12 is an effective anti-cancer therapy, high concentrations may produce unwanted adverse effects or result in immune suppression. We previously demonstrated that intratumor delivery of a plasmid encoding IL-12 with gene electrotransfer (GET) induced local and systemic tumor control with no detected adverse effects. However, the shortcomings of standard GET are that high voltage is required and the lack of a delivery completion signal. We recently developed an improved system that overcomes these issues by incorporating sophisticated electrodes, mild heat application, and real time tissue impedance monitoring. In this study, we validated this advanced electrotransfer system. We compared the therapeutic efficacy of intratumor IL-12 GET in B16-f10 mouse melanomas delivered by standard and advanced technologies. Delivery with both standard and advanced electrotransfer reduced the tumor specific growth rate and increased survival. Our results demonstrated that therapeutic

Indexed as

gene transferheat and impedanceintratumor deliverymelanomaMT: Regular Issuepulse electric fields

Identifiers

PMID40933275
PMCPMC12419079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.